Patient Risk Stratification Market Report 2025

This Patient Risk Stratification market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The patient risk stratification market size has grown exponentially in recent years. It will grow from $2.15 billion in 2024 to $2.82 billion in 2025 at a compound annual growth rate (CAGR) of 31.3%. The growth during the historical period can be attributed to the growing adoption of digitization, increased health risks, an aging population, a rise in medical errors, and the widespread use of electronic health records (EHR).

The patient risk stratification market size is expected to see exponential growth in the next few years. It will grow to $8.3 billion in 2029 at a compound annual growth rate (CAGR) of 31%. Looking ahead, growth during the forecast period is expected to be driven by the expanding middle class and health insurance coverage, the increasing prevalence of chronic diseases, the rising adoption of predictive analytics, a greater focus on social determinants of health (SDOH), and the broader use of technology. Key trends in the forecast period include advancements in analytics, artificial intelligence (AI), machine learning, healthcare technological innovations, wearable technology, and remote monitoring.

The increasing burden of chronic diseases is expected to drive the growth of the patient risk stratification market. Chronic diseases are long-term health conditions that typically last for three months or longer. The rise in chronic diseases can be attributed to several factors, including an aging population, unhealthy lifestyles, urbanization, environmental factors, limited access to healthcare, economic disparities, and elevated stress levels. Patient risk stratification helps identify individuals at varying risk levels for chronic diseases, enabling personalized care, early intervention, better resource management, and improved health outcomes. For example, in January 2023, the National Center for Biotechnology Information (NCBI) projected that the number of individuals aged 50 and older with at least one chronic illness will increase by 99.5%, from 71.5 million in 2020 to 142.7 million by 2050. Additionally, the World Health Organization (WHO) highlighted in September 2022 that chronic diseases are responsible for 74% of all deaths globally, equating to 41 million deaths annually. Cardiovascular diseases account for 17.9 million deaths, cancer causes 9.3 million, chronic respiratory diseases lead to 4.1 million deaths, and diabetes results in 2 million deaths. Consequently, the rising prevalence of chronic diseases is a major driver of the patient risk stratification market.

Companies in the patient risk stratification market are advancing healthcare technologies, such as artificial intelligence (AI) in disease screening, to improve early detection, patient outcomes, and reduce healthcare costs by providing more accurate risk assessments and personalized treatment plans. AI in disease screening employs sophisticated algorithms and machine learning to analyze medical data, facilitating early disease detection and improving diagnostic accuracy by quickly processing large datasets. For example, in May 2024, WELL Health Technologies Corporation, a Canadian healthcare company, alongside its investee company HEALWELL AI, launched WELL AI Decision Support (WAIDS). This tool focuses on rare diseases and chronic conditions such as kidney disease, hypertension, and diabetes, offering risk stratification and helping clinicians identify care gaps and actionable data at the point of care.

In December 2023, Healthcare Outcomes Performance Company (HOPCo), a US-based provider specializing in healthcare performance improvement solutions, acquired MyACTome, a US-based company that offers a smartphone platform for assessing fall risk and frailty. This acquisition is aimed at improving patient outcomes and enhancing healthcare efficiency, particularly in patient risk stratification.

Major players in the patient risk stratification market are Bristol-Myers Squibb, Thermo Fisher Scientific Inc., Abbott Laboratories, Sales Force Inc., Medtronic plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Adobe Inc., Persistent Systems, NextGen Healthcare Inc., Health Catalyst, Freenome, Strive Health, Medeanalytics Inc., American Academy of Family Physicians, Lightbeam Health Solutions, Graphnet Health Ltd., Innova Medical Group Inc., Equipo Health Inc., Epic Systems Corporation.

North America was the largest region in the patient risk stratification market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in patient risk stratification report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the patient risk stratification market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Patient risk stratification involves evaluating and classifying patients based on their likelihood of experiencing adverse health events. This process helps identify high-risk individuals for targeted interventions, optimize the use of resources, promote preventive care, improve care coordination, enhance patient outcomes, reduce costs, and aid in managing population health.

The primary types of patient risk stratification include predictive, retrospective, prospective, and concurrent models. Predictive risk stratification models analyze historical and current patient data to predict future health outcomes and identify those at high risk of developing particular conditions or complications. These models consist of software and services, with delivery options available both on-premise and via the cloud. Key applications include risk adjustment, clinical workflows, revenue cycle management, among others, and they are utilized by various end users, including healthcare providers, payers, and others.

The patient risk stratification market research report is one of a series of new reports that provides patient risk stratification market statistics, including patient risk stratification industry global market size, regional shares, competitors with a patient risk stratification market share, detailed patient risk stratification market segments, market trends and opportunities, and any further data you may need to thrive in the patient risk stratification industry. This patient risk stratification market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The patient risk stratification market includes revenues earned by entities by risk assessment and stratification services, telehealth services, medication management services, chronic disease risk assessment services, and genomic risk stratification services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.